Benchling’s Post

🔬 Partnering with a CDMO for AVV viral vector manufacturing is, for some, one of the most pivotal steps in one's genetic medicine journey- a decision and a partnership that could push the boundaries of genetic medicine.  💡The right CDMO isn't just anyone's CDMO. 🤝 The right CDMO is the one that's right for each respective program.  Below, I've summarized a few of the more common observations I gathered on this topic from numerous articles and firsthand feedback.  🧬 Customized Excellence: The right CDMO leads with an ability to substantiate customized excellence. Every project is unique, and so the right CDMO should have the ability to embrace that fact, offering its unique set of solutions, meeting specific needs, and accelerating timelines. 💉 Comprehensive Lifecycle Support: Proceeding from a strong science-driven platform, the right CDMO enables a seamless transition from concept to reality. The right CDMO offers an integrated approach, developing scale-up strategies to establish a seamless transition between the different phases of one's project, from early development to manufacturing GMP material, ensuring the process is robust, scalable, cost-effective, and reproducible. 🔄 Process Optimization Mastery: Ever-aiming for progress while maintaining the highest standards, the right CDMO understands the importance of efficiency in your timelines. The right CDMO excels in process optimization, maximizing productivity without compromising quality. 🌟 Stringent Quality Control: The right CDMO conveys an unwavering commitment to the highest quality standards. Analytical characterization and quality control of AAV vectors are crucial elements at every stage of development and manufacturing. The right CDMO partner will possess robust, accurate, and reproducible analytical methods to accelerate process development and ensure the quality of manufactured vector products. 🙌 The right CDMO shares the same passion, enabling an alliance and an experience beyond manufacturing, a concerted and effective synergy in advancing one's program and revolutionizing the frontiers of genetic medicine.  #GeneticResearch #LifeSciences #BioTech #ProcessDevelopment #CDMO #ViralVectors #AAV

Attention Pharma and Biotech Contract Research Organizations (#CRO)! Do you have cutting-edge technology that your customers rely on—such as advanced cell lines, animal models, or proprietary antibody generation platforms? Do you want to benchmark your technology against the competition? Or are you looking to offer additional services to your clients, enhancing your value proposition and standing out in a crowded marketplace? We can help! Our team leverages advanced technologies like Next-Generation Sequencing (#NGS) and #multiomic analysis, including #spatial_transcritomics, to provide deep insights and comparisons. Here's how we support CROs like yours: -Benchmark your technologies against industry standards using #multiomic data, showing clients the unique advantages of your solutions. -Expand your service offerings by identifying new opportunities for value-added services, guided by cutting-edge insights from #multiomic and spatial analyses. -Data-driven optimization of your platforms, ensuring they meet the highest performance standards, supported by NGS and #multiomic evidence. -Create compelling marketing materials grounded in scientific data, making your technologies’ superiority clear to potential customers. Whether you’re aiming to increase customer satisfaction, differentiate your offerings, or introduce new revenue-generating services, we have the expertise and the tools to help you thrive. Reach out today to xcellerate bio for a free consultation to explore how we can help your CRO harness the power of #NGS, #multiomics, and #spatial_technologies to enhance your market position and deliver exceptional value to your clients.

DoE helps identify critical factors and their optimal settings, allowing researchers to maximize the efficiency, reliability, and effectiveness of drug discovery assays. By using DoE methodologies, scientists can minimize experimental variability, reduce costs, and accelerate the development of new drugs. It plays a crucial role in optimizing assay conditions and improving the success rate of drug discovery efforts. Read more about DoE and how we work towards the future of health: https://lnkd.in/dZQbVH32 #IDOT #Technology #Automation #LifeSciences #LiquidHandling #LabAutomation #Development #DrugDiscovery #Genomics #SyntheticBiology #LaboratoryAutomation #FutureOfHealth

Future of Genetics..!

New kid on the block in the Flagship Pioneering ecosystem! 🎉 Mirai Bio debuted with $50mn funding and an open-source end-to-end development capability #platform for #genetic medicine. For young biotechs with novel targets, this could allow a smoother ride and easier planning on the formulation and manufacturing side which is often a major roadblock before entering the clinic, not to mention the market. #CDMO #Formulation #Manufacturing #celltargeting #geneticmedicine #AI #ML

UGenome People | Husna Rahim Husna Rahim, PharmD serves as UGenome AI’s Manager of Clinical Content. She is passionate about applying scientific research to benefit patients and revolutionize treatment paradigms. With experience in both clinical and commercial healthcare settings, Dr. Rahim uniquely understands the patient perspective as well as business realities. Through her work translating genomic discoveries into practical guidance and empowering more personalized patient care, Husna is advancing the promise of precision medicine at the forefront of pharmacogenomics. Prior to this, she worked in product strategy and brand management for Bayer Pharma's rare disease business unit. #ugenome, #ugenomeai, #ugenomebiotech, #bioinformatics, #biotech, #genetics,

DoE helps identify critical factors and their optimal settings, allowing researchers to maximize the efficiency, reliability, and effectiveness of drug discovery assays. By using DoE methodologies, scientists can minimize experimental variability, reduce costs, and accelerate the development of new drugs. It plays a crucial role in optimizing assay conditions and improving the success rate of drug discovery efforts. Read more about DoE and how we work towards the future of health: https://lnkd.in/dZQbVH32 #IDOT #Technology #Automation #LifeSciences #LiquidHandling #LabAutomation #Development #DrugDiscovery #Genomics #SyntheticBiology #LaboratoryAutomation #FutureOfHealth

🧬💊 A patient's genetic background can influence their response to a drug — an important consideration when designing and testing treatments. Through a collaboration with the European Variation Archive, the Open Targets Platform recently brought in pharmacogenetics data from PharmGKB, adding a new dimension when prioritising targets for drug discovery. In the latest post on our blog, we dive into how we integrated this data, and the new insights it can provide. 👇 Is there other data you want to see in the Platform? Let us know by commenting below!

Sharing data from Dealroom.co showing the GenAI Health landscape with 2024 deal sizes spanning from $15mil - 100m in size. Not seeing the larger deals (yet), but Q2/3 tends to be the most active period for bigger investments. We will be tracking progress monthly via our #AIAccelerator ---> https://lnkd.in/egnuFPiD Snapshot of the top deals in drug discovery AI: 💊 DeepCure $200m valuation and working on biotechnology to drive faster drug discovery - April 2024 💊 Hippocratic AI $500m valuation, working on first-safety focused LLM for healthcare - March 2024 💊 Curve Therapeutics $320m valuation, working on redefining drug discover for efficiency - Feb 2024 💊 Moonwalk Biosciences $274m valuation, focused on precise epigenetic solutions, mapping cellular states at genome level - Jan 2024 #dayonestrategy #genai #drugdiscovery